Trials / Recruiting
RecruitingNCT02071134
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,500 (estimated)
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.
Detailed description
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS system in the treatment of Parkinson's disease. Subjects' improvement in disease symptoms and overall Quality of life will be assessed during the study following DBS and compared with baseline. Additionally, the utilization of Image Guided Programming (IGP) when used as a planning tool for programming of patients is also evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Deep Brain Stimulation (DBS) | Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry. |
Timeline
- Start date
- 2014-03-04
- Primary completion
- 2038-12-01
- Completion
- 2038-12-01
- First posted
- 2014-02-25
- Last updated
- 2026-04-13
Locations
84 sites across 15 countries: United States, Argentina, Austria, Belgium, Canada, France, Germany, Hungary, Israel, Italy, Poland, South Korea, Spain, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT02071134. Inclusion in this directory is not an endorsement.